Akebia Therapeutics (AKBA) Income from Continuing Operations (2013 - 2026)
Akebia Therapeutics (AKBA) reported Income from Continuing Operations of 9054000.0 for Q1 2026, down 248.13% year-over-year from 6112000.0 in Q1 2025, and up 26.05% quarter-over-quarter from 12244000.0 in Q4 2025.
Akebia Therapeutics (AKBA) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has 14 years of Income from Continuing Operations data on file, last reported at 9054000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 9054000.0, down 248.13% year-over-year; the trailing twelve-month figure through Mar 2026 was 20511000.0 (up 54.73% YoY), and the FY2025 annual result was 5345000.0, up 92.3% from the prior year.
- Income from Continuing Operations grew to 9054000.0 in Q1 2026 per AKBA's latest filing, from 12244000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 29038000.0 in Q2 2022 and troughed at 64643000.0 in Q1 2022.
- A 5-year average of 13658764.71 and a median of 11172000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations surged 134.44% in 2022, then tumbled 3814.01% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 6505000.0 in 2022, then jumped by 109.44% to 614000.0 in 2023, then plunged by 3814.01% to 22804000.0 in 2024, then soared by 46.31% to 12244000.0 in 2025, then climbed by 26.05% to 9054000.0 in 2026.
- Business Quant data shows AKBA's Income from Continuing Operations at 9054000.0 in Q1 2026, 12244000.0 in Q4 2025, and 540000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 370.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 21.05 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -92.12 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 118.42 Mn |
| 10 | Akebia Therapeutics | 243.23 Mn | 80.63 Mn | 41.25 Mn | -9.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.05 Mn |
| Dec 31, 2025 | -12.24 Mn |
| Sep 30, 2025 | 540,000.00 |
| Jun 30, 2025 | 247,000.00 |
| Mar 31, 2025 | 6.11 Mn |
| Dec 31, 2024 | -22.80 Mn |
| Sep 30, 2024 | -20.04 Mn |
| Jun 30, 2024 | -8.58 Mn |
| Mar 31, 2024 | -17.99 Mn |
| Dec 31, 2023 | 614,000.00 |
| Sep 30, 2023 | -14.49 Mn |
| Jun 30, 2023 | -11.17 Mn |
| Mar 31, 2023 | -26.88 Mn |
| Dec 31, 2022 | -6.51 Mn |
| Sep 30, 2022 | -54.36 Mn |
| Jun 30, 2022 | 29.04 Mn |
| Mar 31, 2022 | -64.64 Mn |
| Dec 31, 2021 | -70.42 Mn |
| Sep 30, 2021 | -59.97 Mn |
| Jun 30, 2021 | -84.30 Mn |